Go Pro
→ The retirement stock I'd buy before Nvidia today (From Chaikin Analytics) (Ad)tc pixel Free ZSQR Stock Alerts

Coeptis Therapeutics (ZSQR) Financials

Coeptis Therapeutics logo
$3.85 -0.01 (-0.26%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for Coeptis Therapeutics

Annual Income Statements for Coeptis Therapeutics

This table shows Coeptis Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -0.00 -17 -13 -38 -21 -11 -12
Consolidated Net Income / (Loss)		 -0.00 -17 -13 -38 -21 -11 -12
Net Income / (Loss) Continuing Operations		 -0.00 -17 -13 -38 -21 -11 -12
Total Pre-Tax Income 		-0.00 -17 -13 -38 -21 -11 -12
Total Operating Income		 -0.00 -0.07 -14 -34 -21 -10 -13
Total Gross Profit		 0.00 0.00 0.08 0.00 0.00 0.00 1.18
Total Revenue		 0.00 0.00 0.08 0.00 0.00 0.00 1.36
Operating Revenue		 - - 0.08 0.00 0.00 0.00 1.36
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.18
Operating Cost of Revenue		 - - 0.00 0.00 0.00 0.00 0.18
Total Operating Expenses		 0.00 0.07 14 34 21 10 14
Selling, General & Admin Expense		 0.00 0.07 14 34 12 3.90 8.94
Marketing Expense		 - - 0.00 0.01 - 0.00 0.11
Research & Development Expense		 - - 0.00 0.02 6.67 2.33 1.28
Amortization Expense		 - - - - - 1.00 1.00
Other Operating Expenses / (Income)		 - - - - 1.45 2.83 2.90
Total Other Income / (Expense), net		 0.00 -17 0.60 -3.38 0.22 -0.82 0.77
Interest Expense		 - - 0.19 3.61 0.11 0.46 0.64
Interest & Investment Income		 0.00 0.00 1.00 - - 0.23 -0.05
Other Income / (Expense), net		 0.00 -17 -0.22 0.23 0.33 -0.60 1.46
Income Tax Expense		 - - 0.00 0.00 0.00 0.00 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - 0.00 -0.20 -0.36
Basic Earnings per Share		 $0.00 ($5.63) - - ($16.56) ($5.56) ($2.81)
Weighted Average Basic Shares Outstanding		 0.00 1.19M 1.88M 20.44M 1.28M 1.92M 4.23M
Diluted Earnings per Share		 $0.00 - - - ($16.56) ($5.56) ($2.81)
Weighted Average Diluted Shares Outstanding		 0.00 1.88M 1.88M 20.44M 1.28M 1.92M 4.23M
Weighted Average Basic & Diluted Shares Outstanding		 0.00 1.88M 1.88M 20.44M 36.09M 3.36M 6.22M

Quarterly Income Statements for Coeptis Therapeutics

This table shows Coeptis Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -3.76 -3.00 -3.04 -3.66 -0.99 -3.49 0.00 -5.80 5.86 -4.13 -28
Consolidated Net Income / (Loss)		 -3.76 -3.00 -3.04 -1.83 -3.01 -6.78 0.00 -2.90 -1.62 -7.94 -28
Net Income / (Loss) Continuing Operations		 -3.76 -3.00 -3.04 -1.83 -3.01 -3.42 0.00 -2.90 -2.42 -4.02 -28
Total Pre-Tax Income 		-3.76 -3.00 -3.04 -1.83 -3.01 -3.42 0.00 -2.90 -1.62 -4.02 -14
Total Operating Income		 -3.37 -2.92 -2.83 -2.14 -2.16 -4.06 0.00 -2.48 -1.99 -3.91 -14
Total Gross Profit		 - 0.00 0.00 0.00 - 0.02 0.00 0.19 0.82 0.07 -1.77
Total Revenue		 - 0.00 0.00 0.00 - 0.06 0.00 0.24 0.86 0.11 3.17
Operating Revenue		 - 0.00 0.00 0.00 - 0.06 - 0.24 0.86 0.11 3.17
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.05 0.00 0.05 0.05 0.05 6.70
Operating Cost of Revenue		 - 0.00 0.00 0.00 - 0.05 0.00 0.05 0.05 0.05 6.70
Total Operating Expenses		 3.37 2.92 2.83 2.14 2.16 4.07 0.00 2.67 2.81 3.98 24
Selling, General & Admin Expense		 1.43 1.35 1.10 0.60 0.83 2.59 0.00 1.26 1.58 1.66 4.21
Marketing Expense		 - 0.00 0.01 0.00 -0.01 0.11 0.00 0.00 -0.00 0.00 0.01
Amortization Expense		 - - - 0.25 - 0.25 0.00 0.25 - 0.25 0.12
Other Operating Expenses / (Income)		 0.44 0.54 1.07 0.48 0.74 1.04 0.00 0.57 0.66 1.84 19
Impairment Charge		 - - - - - - 0.00 - - - 0.31
Total Other Income / (Expense), net		 -0.39 -0.08 -0.21 0.31 -0.85 0.64 0.00 -0.42 0.37 -0.11 -0.00
Interest Expense		 0.01 0.20 0.07 0.05 0.14 0.07 0.00 0.06 0.44 0.01 0.00
Other Income / (Expense), net		 -0.38 0.12 -0.14 0.36 -0.94 0.71 0.00 -0.36 0.85 -0.08 -0.00
Income Tax Expense		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 - 0.00 0.00 0.10 -0.29 0.06 0.00 0.16 -1.68 0.10 0.07
Basic Earnings per Share		 ($2.92) ($0.08) - - ($0.51) ($1.10) $0.00 - $1.38 ($0.65) ($0.28)
Weighted Average Basic Shares Outstanding		 1.28M 35.54M 39.72M 41.12M 1.92M 3.07M 43.88M 5.34M 4.23M 6.03M 49.76M
Diluted Earnings per Share		 ($2.92) ($0.08) - - ($0.51) ($1.10) $0.00 - $1.38 ($0.65) ($0.28)
Weighted Average Diluted Shares Outstanding		 1.28M 35.54M 39.72M 41.12M 1.92M 3.07M 43.88M 5.34M 4.23M 6.03M 49.76M
Weighted Average Basic & Diluted Shares Outstanding		 36.09M 37.12M 39.72M 41.12M 3.36M 3.51M 4.82M 5.34M 6.22M 51.43M 53.00M

Annual Cash Flow Statements for Coeptis Therapeutics

This table details how cash moves in and out of Coeptis Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.00 0.91 1.98 1.61 -2.32 -0.94 5.14
Net Cash From Operating Activities		 -0.00 -0.12 -4.49 -3.88 -7.24 -6.65 -8.60
Net Cash From Continuing Operating Activities		 -0.00 -0.12 -4.49 -3.88 -7.24 -6.65 -8.60
Net Income / (Loss) Continuing Operations		 -0.00 -17 -13 -38 -21 -11 -12
Consolidated Net Income / (Loss)		 -0.00 -17 -13 -38 -21 -11 -12
Depreciation Expense		 - - 0.45 1.00 1.00 1.00 1.18
Amortization Expense		 - - - - 0.03 0.25 0.59
Non-Cash Adjustments To Reconcile Net Income		 0.00 17 11 33 11 2.25 4.22
Changes in Operating Assets and Liabilities, net		 0.00 -0.05 -2.98 -0.55 1.77 0.72 -2.32
Net Cash From Investing Activities		 0.00 -76 -1.75 0.00 0.00 0.00 0.00
Net Cash From Continuing Investing Activities		 0.00 -76 -1.75 0.00 0.00 0.00 0.00
Net Cash From Financing Activities		 0.00 77 8.22 5.49 4.92 5.71 14
Net Cash From Continuing Financing Activities		 0.00 77 8.22 5.49 4.92 5.71 14
Repayment of Debt		 0.00 -0.19 -1.70 -2.42 -1.23 -0.65 -0.22
Issuance of Debt		 0.09 0.04 0.08 0.00 0.65 1.85 0.99
Issuance of Preferred Equity		 - - - - - 3.91 5.46
Issuance of Common Equity		 0.00 77 10 3.27 5.49 0.60 4.56
Other Financing Activities, net		 - - -0.05 4.63 - 0.00 2.96
Cash Interest Paid		 - - 0.00 0.00 0.00 0.01 0.01
Cash Income Taxes Paid		 - - 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Coeptis Therapeutics

This table details how cash moves in and out of Coeptis Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 0.06 -0.44 0.53 -0.42 -0.60 3.74 -2.27 2.91 0.77 -0.46 16
Net Cash From Operating Activities		 -1.69 -1.90 -1.42 -1.89 -1.44 -2.37 -2.40 -2.15 -1.69 -1.76 1.56
Net Cash From Continuing Operating Activities		 -1.69 -1.90 -1.42 -1.89 -1.44 -2.37 -2.40 -2.15 -1.69 -1.76 1.56
Net Income / (Loss) Continuing Operations		 -3.76 -3.00 -3.04 -1.83 -3.01 -3.42 -4.33 -2.90 -1.62 -4.02 -9.77
Consolidated Net Income / (Loss)		 -3.76 -3.00 -3.04 -1.83 -3.01 -3.42 -4.33 -2.90 -1.62 -4.02 -9.77
Depreciation Expense		 0.25 0.25 0.25 0.25 0.25 0.30 0.30 0.30 0.30 0.30 0.86
Amortization Expense		 0.00 0.16 -0.01 0.03 0.08 0.11 0.40 0.07 0.01 0.02 0.10
Non-Cash Adjustments To Reconcile Net Income		 0.90 0.54 1.31 -0.23 0.62 1.18 3.03 0.81 -0.50 1.45 9.44
Changes in Operating Assets and Liabilities, net		 0.91 0.15 0.06 -0.11 0.63 -0.53 -1.79 -0.43 0.12 0.50 0.92
Net Cash From Investing Activities		 - -0.10 - - 0.10 0.00 - - - 0.59 -0.59
Net Cash From Continuing Investing Activities		 - -0.10 - - 0.10 0.00 - - - 0.59 -0.59
Sale and/or Maturity of Investments		 - - - - - 0.00 - - - 0.59 -0.59
Net Cash From Financing Activities		 1.75 1.56 1.94 1.47 0.73 6.10 0.13 5.06 2.45 0.70 15
Net Cash From Continuing Financing Activities		 1.75 1.56 1.94 1.47 0.73 6.10 0.13 5.06 2.45 0.70 -0.43
Issuance of Debt		 0.15 1.35 0.50 - - 0.99 - - - 0.00 0.28
Cash Interest Paid		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.00

Annual Balance Sheets for Coeptis Therapeutics

This table presents Coeptis Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.17 77 6.77 7.92 4.57 8.91 0.00
Total Current Assets		 0.00 0.96 2.18 3.94 1.75 1.05 0.00
Cash & Equivalents		 0.00 0.91 2.18 3.79 1.47 0.53 0.00
Prepaid Expenses		 0.00 0.05 0.00 0.14 0.24 0.52 0.00
Plant, Property, & Equipment, net		 0.00 0.00 0.01 0.01 0.01 0.01 0.00
Total Noncurrent Assets		 0.17 76 4.57 3.96 2.81 7.85 0.00
Long-Term Investments		 0.00 76 - - - - 0.00
Goodwill		 - - - - - - 0.00
Other Noncurrent Operating Assets		 0.17 - 4.57 3.96 2.81 7.31 0.00
Total Liabilities & Shareholders' Equity		 0.17 77 6.77 7.92 4.57 8.91 0.00
Total Liabilities		 0.16 23 4.41 3.46 3.76 5.04 0.00
Total Current Liabilities		 0.16 0.01 2.76 2.17 2.99 4.51 0.00
Accounts Payable		 0.00 0.01 0.13 0.10 1.42 1.27 0.00
Accrued Expenses		 0.00 - 0.20 0.18 0.56 0.74 0.00
Other Current Liabilities		 - - 0.01 0.04 0.04 1.32 0.00
Total Noncurrent Liabilities		 0.00 23 1.65 1.29 0.77 0.53 0.00
Other Noncurrent Operating Liabilities		 0.00 23 0.00 1.14 0.62 0.38 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.02 -22 2.35 4.45 0.81 3.87 0.00
Total Preferred & Common Equity		 0.02 -22 2.35 4.45 0.81 3.38 0.00
Preferred Stock		 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Common Equity		 0.02 -22 2.35 4.45 0.81 3.38 0.00
Common Stock		 0.03 0.03 30 71 92 103 0.00
Retained Earnings		 -0.01 -22 -28 -66 -87 -98 -0.00
Noncontrolling Interest		 - - - - 0.00 0.49 0.00

Quarterly Balance Sheets for Coeptis Therapeutics

This table presents Coeptis Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 7.16 4.67 3.89 4.20 8.96 13 12 14 20 135
Total Current Assets		 3.80 1.62 1.38 1.99 1.36 4.65 3.69 5.99 5.91 16
Cash & Equivalents		 3.24 1.41 1.03 1.56 1.14 4.27 2.00 4.91 5.21 15
Prepaid Expenses		 0.20 0.21 0.24 0.24 0.23 0.38 0.68 0.57 0.63 0.03
Plant, Property, & Equipment, net		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 11
Total Noncurrent Assets		 3.35 3.04 2.50 2.20 7.58 8.79 8.49 8.18 14 108
Goodwill		 - - - - - - - - - 107
Other Noncurrent Operating Assets		 0.29 0.23 2.50 2.20 7.58 8.30 8.03 7.77 14 0.77
Total Liabilities & Shareholders' Equity		 7.16 4.67 3.89 4.20 8.96 13 12 14 20 135
Total Liabilities		 5.20 2.78 5.03 4.51 3.97 5.99 5.11 3.26 2.21 2.03
Total Current Liabilities		 3.04 2.23 4.30 3.63 3.44 5.65 4.48 2.71 1.82 2.03
Accounts Payable		 0.40 0.48 1.37 1.28 1.13 1.12 1.03 0.78 1.01 1.38
Accrued Expenses		 0.43 0.57 0.72 0.77 0.74 0.60 0.42 0.21 0.06 0.52
Other Current Liabilities		 0.02 0.01 0.03 0.02 0.01 0.90 0.26 0.15 0.16 0.12
Total Noncurrent Liabilities		 2.15 0.54 0.73 0.88 0.53 0.34 0.64 0.56 0.39 0.00
Other Noncurrent Operating Liabilities		 2.00 0.39 0.58 0.73 0.38 0.19 0.49 0.41 0.24 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1.96 1.89 -1.14 -0.31 4.98 7.46 7.08 11 18 132
Total Preferred & Common Equity		 1.96 1.89 -1.14 -0.44 4.82 6.48 6.10 10 17 132
Preferred Stock		 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1.96 1.89 -1.14 -0.44 4.82 6.48 6.10 10 17 132
Common Stock		 79 88 95 101 102 108 112 121 135 146
Retained Earnings		 -77 -84 -90 -93 -95 -102 -106 -108 -114 -14
Noncontrolling Interest		 - - - 0.13 0.16 0.98 0.98 0.55 0.40 0.00

Annual Metrics And Ratios for Coeptis Therapeutics

This table displays calculated financial ratios and metrics derived from Coeptis Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 9,656,250.00 9,375,000.00 5,116,414.00 102,324,108.00 41,118,593.00 5,340,111.00
DEI Adjusted Shares Outstanding		 0.00 482,813.00 468,750.00 255,821.00 5,116,205.00 2,055,930.00 5,340,111.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -35.79 -28.69 -146.88 -4.16 -5.19 -2.23
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -773,444.32% 20.06% -138.59% 38.95% 53.31% -4.52%
EBIT Growth		 0.00% -773,444.32% 17.47% -138.13% 37.70% 49.67% -8.81%
NOPAT Growth		 0.00% -2,963.12% -20,425.99% -143.46% 37.15% 53.22% -29.73%
Net Income Growth		 0.00% -773,390.42% 22.17% -179.38% 43.40% 48.85% -12.87%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 48.85% 49.46%
Operating Cash Flow Growth		 0.00% -6,385.15% -3,780.41% 13.67% -86.79% 8.15% -29.38%
Free Cash Flow Firm Growth		 0.00% 0.00% -260.59% 39.52% 42.53% 12.54% -10.54%
Invested Capital Growth		 0.00% -13,746.49% 118.50% -37.19% -82.35% 894.45% 70.52%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 172.07%
EBITDA Q/Q Growth		 0.00% 0.00% -1,544.21% 46.74% -4.83% 7.04% 13.84%
EBIT Q/Q Growth		 0.00% 0.00% -1,597.46% 45.12% -4.76% 5.67% 12.12%
NOPAT Q/Q Growth		 0.00% 0.00% -2,919.64% 23.58% -1.26% 10.69% 1.32%
Net Income Q/Q Growth		 0.00% 0.00% -1,514.02% 41.77% -3.97% 6.40% 10.16%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 6.40% 49.73%
Operating Cash Flow Q/Q Growth		 0.00% -6,673.71% -926.63% 46.13% -13.24% 3.72% -3.01%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 32.33% 39.03% 3.29% -30.25%
Invested Capital Q/Q Growth		 0.00% 0.00% 169.02% 160.27% -73.99% -15.80% 36.51%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 86.75%
EBITDA Margin		 0.00% 0.00% -18,419.64% 0.00% 0.00% 0.00% -720.41%
Operating Margin		 0.00% 0.00% -18,727.91% 0.00% 0.00% 0.00% -956.94%
EBIT Margin		 0.00% 0.00% -19,016.19% 0.00% 0.00% 0.00% -850.14%
Profit (Net Income) Margin		 0.00% 0.00% -17,932.37% 0.00% 0.00% 0.00% -900.72%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 99.99% 94.30% 110.64% 100.51% 102.14% 105.95%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -144.48%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -25.64%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.57%
Return on Equity (ROE)		 -14.24% -64.27% -47.94% -1,104.48% -807.49% -464.73% -136.90%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -872.41% -648.14% -820.70% -437.20% -196.61%
Operating Return on Assets (OROA)		 0.00% 0.00% -34.17% 0.00% 0.00% 0.00% -92.47%
Return on Assets (ROA)		 0.00% 0.00% -32.22% 0.00% 0.00% 0.00% -97.97%
Return on Common Equity (ROCE)		 -14.24% 26.27% 16.79% -1,104.48% -807.49% -416.57% -129.34%
Return on Equity Simple (ROE_SIMPLE)		 -14.24% 78.56% -572.16% -843.73% -2,612.71% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.00 -0.05 -9.83 -24 -15 -7.04 -9.13
NOPAT Margin		 0.00% 0.00% -13,109.54% 0.00% 0.00% 0.00% -669.86%
Net Nonoperating Expense Percent (NNEP)		 0.44% -45.05% -9.68% 28,369.13% -582.81% 1,666.15% -118.84%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -775.87% -135.22% -63.77%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13.25%
SG&A Expenses to Revenue		 0.00% 0.00% 18,824.02% 0.00% 0.00% 0.00% 655.89%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 93.70%
Operating Expenses to Revenue		 0.00% 0.00% 18,827.91% 0.00% 0.00% 0.00% 1,043.69%
Earnings before Interest and Taxes (EBIT)		 -0.00 -17 -14 -34 -21 -11 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.00 -17 -14 -33 -20 -9.40 -9.82
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 4,779.20 0.00 39.88 1.76 32.85 3.34 5.61
Price to Tangible Book Value (P/TBV)		 4,779.20 0.00 39.88 1.76 32.85 3.98 5.76
Price to Revenue (P/Rev)		 0.00 0.00 1,250.00 0.00 0.00 0.00 55.83
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 447.78 0.00 22.57 2.27 56.18 2.70 8.85
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 1,275.17 0.00 0.00 0.00 51.72
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 4.23 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 9.73 0.00 1.73 0.45 1.38 0.35 0.02
Long-Term Debt to Equity		 0.00 0.00 0.70 0.03 0.18 0.04 0.01
Financial Leverage		 9.69 -1.42 -1.33 0.01 -0.41 0.10 -0.30
Leverage Ratio		 10.93 1.43 1.49 2.16 2.37 2.88 1.40
Compound Leverage Factor		 10.93 1.43 1.40 2.39 2.38 2.94 1.48
Debt to Total Capital		 90.68% 0.00% 63.37% 30.99% 58.02% 25.70% 1.75%
Short-Term Debt to Total Capital		 90.68% 0.00% 37.66% 28.67% 50.28% 22.82% 0.70%
Long-Term Debt to Total Capital		 0.00% 0.00% 25.71% 2.32% 7.74% 2.88% 1.05%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 140.92% 0.00% 0.00% 0.00% 9.32% 3.54%
Common Equity to Total Capital		 9.32% -40.92% 36.63% 69.01% 41.98% 64.98% 94.72%
Debt to EBITDA		 -68.33 0.00 -0.29 -0.06 -0.06 -0.14 -0.03
Net Debt to EBITDA		 -68.10 0.00 -0.14 0.05 0.02 -0.09 0.62
Long-Term Debt to EBITDA		 0.00 0.00 -0.12 0.00 -0.01 -0.02 -0.02
Debt to NOPAT		 -97.61 0.00 -0.41 -0.08 -0.07 -0.19 -0.03
Net Debt to NOPAT		 -97.29 0.00 -0.19 0.07 0.02 -0.11 0.67
Long-Term Debt to NOPAT		 0.00 0.00 -0.17 -0.01 -0.01 -0.02 -0.02
Altman Z-Score		 287.53 1.44 -0.01 -24.22 -38.09 -18.47 10.49
Noncontrolling Interest Sharing Ratio		 0.00% 140.88% 135.01% 0.00% 0.00% 10.36% 5.53%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 191.80 0.79 1.81 0.59 0.23 4.16
Quick Ratio		 0.00 181.44 0.79 1.75 0.50 0.12 3.60
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 23 -37 -22 -13 -11 -12
Operating Cash Flow to CapEx		 0.00% 0.00% -256.54% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -197.58 -6.19 -119.34 -24.31 -19.34
Operating Cash Flow to Interest Expense		 0.00 0.00 -23.99 -1.07 -67.23 -14.38 -13.39
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -33.34 -1.07 -67.23 -14.38 -13.39
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.11
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 134.07
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.17
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 2,180.92
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 -2,180.92
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.17 -23 4.24 2.66 0.47 4.67 7.97
Invested Capital Turnover		 0.00 0.00 -0.01 0.00 0.00 0.00 0.22
Increase / (Decrease) in Invested Capital		 0.00 -23 27 -1.58 -2.19 4.20 3.30
Enterprise Value (EV)		 75 97 96 6.04 26 13 71
Market Capitalization		 75 98 94 7.83 27 11 76
Book Value per Share		 $0.01 ($2.28) $0.25 $0.87 $0.02 $0.08 $2.54
Tangible Book Value per Share		 $0.01 ($2.28) $0.25 $0.87 $0.02 $0.07 $2.47
Total Capital		 0.17 54 6.42 6.45 1.94 5.21 14
Total Debt		 0.15 0.00 4.07 2.00 1.13 1.34 0.25
Total Long-Term Debt		 0.00 0.00 1.65 0.15 0.15 0.15 0.15
Net Debt		 0.15 -77 1.89 -1.79 -0.34 0.80 -6.10
Capital Expenditures (CapEx)		 0.00 0.00 1.75 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.00 0.05 -0.35 -0.17 -1.73 -2.81 -0.67
Debt-free Net Working Capital (DFNWC)		 -0.00 0.95 1.83 3.62 -0.26 -2.27 5.68
Net Working Capital (NWC)		 -0.16 0.95 -0.59 1.77 -1.24 -3.46 5.58
Net Nonoperating Expense (NNE)		 0.00 17 3.62 14 6.22 3.84 3.15
Net Nonoperating Obligations (NNO)		 0.15 -77 1.89 -1.79 -0.34 0.80 -6.10
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.45 1.00 1.04 1.25 1.77
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -463.92% 0.00% 0.00% 0.00% -49.07%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 2,442.15% 0.00% 0.00% 0.00% 416.86%
Net Working Capital to Revenue		 0.00% 0.00% -780.51% 0.00% 0.00% 0.00% 409.53%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $1.62 $0.00 $0.00 ($5.65) ($2.81)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 7.50M 0.00 0.00 1.92M 4.23M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($5.65) ($2.81)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 1.88M 0.00 0.00 1.92M 4.23M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 1.88M 0.00 0.00 3.36M 6.22M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.00 -0.05 -9.83 -24 -15 -7.04 -9.13
Normalized NOPAT Margin		 0.00% 0.00% -13,109.54% 0.00% 0.00% 0.00% -669.86%
Pre Tax Income Margin		 0.00% 0.00% -17,932.37% 0.00% 0.00% 0.00% -900.72%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -76.21 -9.40 -196.49 -23.04 -18.04
NOPAT to Interest Expense		 0.00 0.00 -52.54 -6.63 -139.70 -15.22 -14.21
EBIT Less CapEx to Interest Expense		 0.00 0.00 -85.57 -9.40 -196.49 -23.04 -18.04
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -61.89 -6.63 -139.70 -15.22 -14.21
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -3,951.75% -1.88% -1.84% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Coeptis Therapeutics

This table displays calculated financial ratios and metrics derived from Coeptis Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 102,324,108.00 72,179,834.00 74,237,186.00 39,718,593.00 41,118,593.00 3,364,939.00 3,513,838.00 4,820,317.00 5,340,111.00 6,223,221.00 51,431,493.00
DEI Adjusted Shares Outstanding		 5,116,205.00 3,608,992.00 3,711,859.00 1,985,930.00 2,055,930.00 3,364,939.00 3,513,838.00 4,820,317.00 5,340,111.00 6,223,221.00 51,431,493.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.73 -0.83 -0.82 -1.84 -0.48 -1.04 -1.46 -1.20 1.10 -0.66 -0.54
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 80.95% 0.00%
EBITDA Growth		 -37.83% 68.84% 6.24% 75.21% 20.41% -23.11% -30.98% -64.85% 70.12% -25.07% -3,066.28%
EBIT Growth		 -34.58% 64.66% 6.03% 71.91% 17.11% -19.59% -43.70% -59.51% 63.39% -19.21% 0.00%
NOPAT Growth		 -8.61% 55.31% 23.25% 72.89% 35.76% -38.82% -59.87% -15.65% 8.04% 3.51% 0.00%
Net Income Growth		 -27.61% 62.28% 5.22% 71.20% 19.81% -125.81% -42.80% -58.50% 46.11% -17.12% 0.00%
EPS Growth		 0.00% 62.28% 0.00% 0.00% 19.81% -1,275.00% 0.00% 0.00% 370.59% 40.91% 0.00%
Operating Cash Flow Growth		 -99.89% -12.94% 25.50% 3.36% 15.19% -24.38% -69.05% -13.72% -17.50% 25.67% -34.24%
Free Cash Flow Firm Growth		 72.36% 83.77% 89.83% 55.40% -3,385.71% -433.08% -1,057.09% 61.43% 18.00% -28.86% -2,086.46%
Invested Capital Growth		 -82.35% -77.34% -115.13% 207.19% 894.45% 2,992.57% 3,440.35% 5.18% 70.52% 142.43% 2,072.59%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 219.18% 18.32% 263.06% -86.80% 2,683.64%
EBITDA Q/Q Growth		 42.36% 31.42% -14.08% 45.03% -85.06% -6.08% -21.37% 30.81% 66.45% -343.99% -248.38%
EBIT Q/Q Growth		 40.90% 25.15% -6.01% 40.12% -74.45% -7.99% -27.39% 33.53% 59.97% -251.68% -245.48%
NOPAT Q/Q Growth		 57.40% 13.18% 3.23% 24.27% -0.95% -87.63% -11.44% 45.21% 19.73% -96.89% -252.38%
Net Income Q/Q Growth		 40.86% 20.08% -1.13% 39.75% -64.68% -125.03% -26.71% 33.12% 44.01% -389.09% -246.67%
EPS Q/Q Growth		 40.86% 20.08% 0.00% 0.00% 0.00% -115.69% 0.00% 0.00% 0.00% -147.10% 56.92%
Operating Cash Flow Q/Q Growth		 13.51% -12.32% 25.48% -33.50% 24.10% -64.71% -1.29% 10.20% 21.57% -4.21% 188.47%
Free Cash Flow Firm Q/Q Growth		 98.60% -798.70% 48.92% -596.28% -9.05% -37.44% -10.88% 76.79% -131.84% -116.00% -1,097.82%
Invested Capital Q/Q Growth		 -73.99% -64.32% -196.17% 3,542.11% -15.80% 10.95% 3.88% 8.39% 36.51% 57.73% 830.93%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 28.18% 77.50% 80.98% 94.76% 60.31% -55.76%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -4,682.82% -1,780.69% -1,041.27% -96.21% -3,236.72% -405.09%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -6,452.56% -2,252.94% -1,043.22% -230.64% -3,440.81% -435.58%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -5,327.24% -2,126.16% -1,194.47% -131.71% -3,509.64% -435.58%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -10,779.46% -2,159.94% -1,220.84% -188.26% -6,976.75% -868.88%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 198.12% 100.00% 100.00% 100.00% 197.41% 199.48%
Interest Burden Percent		 100.37% 107.16% 102.22% 102.86% 97.10% 102.13% 101.59% 102.21% 142.94% 100.70% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -106.14% -159.14% -64.27% -34.82% -383.71% -22.83%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 705.01% -7.86% -12.65% -26.09% -241.14% 185.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% -108.26% 1.79% 3.59% 7.71% 70.21% -22.78%
Return on Equity (ROE)		 -807.49% 11,086.70% -1,956.25% -338.06% -464.73% -214.40% -157.34% -60.67% -27.12% -313.50% -45.61%
Cash Return on Invested Capital (CROIC)		 -820.70% -2,632.34% 0.00% -316.05% -437.20% -480.19% -270.46% -167.58% -196.61% -184.94% -212.94%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -38.62% -68.38% -51.73% -14.33% -298.58% -27.20%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -78.14% -69.47% -52.87% -20.48% -593.55% -54.26%
Return on Common Equity (ROCE)		 -807.49% 11,086.70% -1,799.19% -330.30% -416.57% -181.02% -131.39% -57.97% -25.62% -296.15% -45.29%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 1,429.91% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.36 -2.05 -1.98 -1.50 -1.51 -2.84 -3.16 -1.73 -1.39 -2.74 -9.66
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -4,516.79% -1,577.06% -730.25% -161.45% -2,408.57% -304.90%
Net Nonoperating Expense Percent (NNEP)		 -131.07% 159.10% -283.04% 137.37% 650.19% -811.15% -151.28% -51.61% -8.73% -142.57% -207.83%
Return On Investment Capital (ROIC_SIMPLE)		 -121.52% -170.92% -142.03% -22.42% -29.08% -30.04% -37.80% -15.53% -9.72% -15.37% -7.29%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 71.82% 22.50% 19.02% 5.24% 39.69% 211.52%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 4,126.73% 1,745.37% 532.13% 183.21% 1,458.06% 133.01%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 137.83% 144.66% 247.34% 36.30% 207.02% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 6,480.74% 2,330.43% 1,124.20% 325.41% 3,501.12% 757.27%
Earnings before Interest and Taxes (EBIT)		 -3.74 -2.80 -2.97 -1.78 -3.10 -3.35 -4.27 -2.84 -1.14 -3.99 -14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.49 -2.39 -2.73 -1.50 -2.78 -2.94 -3.57 -2.47 -0.83 -3.68 -13
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 32.85 0.00 0.00 1.48 3.34 4.87 4.50 8.12 5.61 4.07 4.11
Price to Tangible Book Value (P/TBV)		 32.85 0.00 0.00 1.48 3.98 5.27 4.86 8.45 5.76 4.14 21.30
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 501.47 103.99 167.99 55.83 49.38 118.79
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 56.18 71.84 0.00 1.42 2.70 5.83 4.96 13.64 8.85 5.19 4.52
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 480.88 101.30 158.95 51.72 46.12 115.40
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.38 -2.05 -5.50 0.34 0.35 0.27 0.18 0.02 0.02 0.01 0.00
Long-Term Debt to Equity		 0.18 -0.13 -0.48 0.03 0.04 0.02 0.02 0.01 0.01 0.01 0.00
Financial Leverage		 -0.41 -4.08 -0.45 0.07 0.10 -0.15 -0.23 -0.28 -0.30 -0.29 -0.12
Leverage Ratio		 2.37 -33.43 6.88 1.98 2.88 2.74 2.42 1.46 1.40 1.33 1.05
Compound Leverage Factor		 2.38 -35.83 7.03 2.04 2.80 2.80 2.46 1.49 2.00 1.34 1.05
Debt to Total Capital		 58.02% 195.30% 122.24% 25.48% 25.70% 21.05% 15.43% 2.24% 1.75% 1.40% 0.00%
Short-Term Debt to Total Capital		 50.28% 182.77% 111.48% 23.24% 22.82% 19.46% 13.64% 0.90% 0.70% 0.56% 0.00%
Long-Term Debt to Total Capital		 7.74% 12.53% 10.76% 2.24% 2.88% 1.59% 1.79% 1.34% 1.05% 0.84% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 9.51% 2.36% 9.32% 10.41% 11.76% 4.94% 3.54% 2.25% 0.00%
Common Equity to Total Capital		 41.98% -95.30% -31.75% 72.16% 64.98% 68.54% 72.81% 92.83% 94.72% 96.34% 100.00%
Debt to EBITDA		 -0.06 -0.16 -0.12 -0.17 -0.14 -0.20 -0.12 -0.02 -0.03 -0.02 0.00
Net Debt to EBITDA		 0.02 -0.09 -0.01 -0.06 -0.09 0.23 0.16 0.45 0.62 0.47 0.00
Long-Term Debt to EBITDA		 -0.01 -0.01 -0.01 -0.01 -0.02 -0.02 -0.01 -0.01 -0.02 -0.01 0.00
Debt to NOPAT		 -0.07 -0.19 -0.14 -0.22 -0.19 -0.25 -0.14 -0.03 -0.03 -0.03 0.00
Net Debt to NOPAT		 0.02 -0.10 -0.01 -0.07 -0.11 0.29 0.19 0.55 0.67 0.56 0.00
Long-Term Debt to NOPAT		 -0.01 -0.01 -0.01 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02 0.00
Altman Z-Score		 -25.51 -34.48 -32.52 -14.74 -15.68 -8.33 -10.16 4.42 12.63 10.57 160.78
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 8.03% 2.29% 10.36% 15.57% 16.50% 4.46% 5.53% 5.54% 0.71%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.59 0.32 0.55 0.40 0.23 0.82 0.83 2.21 4.16 3.25 7.66
Quick Ratio		 0.50 0.26 0.48 0.33 0.12 0.76 0.67 2.00 3.60 2.90 7.64
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.16 -1.47 -0.75 -5.24 -5.72 -7.86 -8.71 -2.02 -4.69 -10 -121
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -11.86 -7.35 -11.40 -102.93 -39.47 -109.89 -128.50 -32.29 -10.64 -1,925.73 -536,557.50
Operating Cash Flow to Interest Expense		 -122.45 -9.49 -21.46 -37.16 -9.92 -33.10 -35.36 -34.38 -3.83 -334.58 6,885.36
Operating Cash Flow Less CapEx to Interest Expense		 -122.45 -9.49 -21.46 -37.16 -9.92 -33.10 -35.36 -34.38 -3.83 -334.58 6,885.36
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.01 0.03 0.04 0.11 0.09 0.06
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 5.87 25.04 48.42 134.07 141.11 0.81
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.04 0.08 0.14 0.17 0.17 5.71
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 10,049.52 4,667.89 2,583.01 2,180.92 2,153.96 63.96
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 -10,049.52 -4,667.89 -2,583.01 -2,180.92 -2,153.96 -63.96
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.47 0.17 -0.16 5.55 4.67 5.18 5.38 5.84 7.97 13 117
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.02 0.10 0.09 0.22 0.16 0.07
Increase / (Decrease) in Invested Capital		 -2.19 -0.57 -1.23 3.74 4.20 5.02 5.55 0.29 3.30 7.38 112
Enterprise Value (EV)		 26 12 11 7.87 13 30 27 80 71 65 529
Market Capitalization		 27 11 11 7.15 11 32 27 84 76 70 544
Book Value per Share		 $0.02 ($0.03) ($0.01) $0.12 $0.08 $1.93 $1.26 $2.15 $2.54 $2.76 $2.58
Tangible Book Value per Share		 $0.02 ($0.03) ($0.01) $0.12 $0.07 $1.78 $1.17 $2.07 $2.47 $2.71 $0.50
Total Capital		 1.94 1.20 1.39 6.69 5.21 9.45 8.37 11 14 18 132
Total Debt		 1.13 2.34 1.70 1.70 1.34 1.99 1.29 0.25 0.25 0.25 0.00
Total Long-Term Debt		 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.00
Net Debt		 -0.34 1.31 0.15 0.57 0.80 -2.28 -1.70 -5.08 -6.10 -5.01 -15
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.73 -1.76 -1.64 -1.66 -2.81 -3.43 -2.63 -1.94 -0.67 -1.07 -1.99
Debt-free Net Working Capital (DFNWC)		 -0.26 -0.73 -0.08 -0.52 -2.27 0.84 0.36 3.39 5.68 4.19 13
Net Working Capital (NWC)		 -1.24 -2.92 -1.63 -2.08 -3.46 -1.00 -0.78 3.29 5.58 4.09 13
Net Nonoperating Expense (NNE)		 1.40 0.96 1.06 0.33 1.50 3.94 1.17 1.16 0.23 5.20 18
Net Nonoperating Obligations (NNO)		 -0.34 1.31 0.15 0.57 0.80 -2.28 -1.70 -5.08 -6.10 -5.01 -15
Total Depreciation and Amortization (D&A)		 0.25 0.41 0.24 0.28 0.33 0.41 0.69 0.36 0.31 0.31 0.97
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -5,455.80% -996.22% -388.16% -49.07% -75.74% -43.51%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 1,332.96% 137.25% 675.75% 416.86% 296.39% 294.68%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -1,592.32% -296.06% 655.79% 409.53% 289.32% 294.68%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($58.40) $0.00 ($1.60) ($1.00) ($10.20) ($1.11) $0.00 $0.00 $1.38 ($0.65) ($0.28)
Adjusted Weighted Average Basic Shares Outstanding		 64.23K 0.00 1.88M 1.99M 96.23K 3.07M 4.82M 5.34M 4.23M 6.03M 49.76M
Adjusted Diluted Earnings per Share		 ($58.40) $0.00 ($1.60) ($1.00) ($10.20) ($1.11) $0.00 $0.00 $1.38 ($0.65) ($0.28)
Adjusted Weighted Average Diluted Shares Outstanding		 64.23K 0.00 1.88M 1.99M 96.23K 3.07M 4.82M 5.34M 4.23M 6.03M 49.76M
Adjusted Basic & Diluted Earnings per Share		 ($58.40) $0.00 $0.00 $0.00 ($10.20) $0.00 $0.00 $0.00 $1.38 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.80M 0.00 1.99M 2.06M 168.25K 3.51M 4.82M 5.34M 6.22M 51.43M 53.00M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.36 -2.05 -1.98 -1.50 -1.51 -2.84 -3.16 -1.73 -1.39 -2.74 -9.44
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -4,516.79% -1,577.06% -730.25% -161.45% -2,408.57% -298.13%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -5,440.95% -2,159.94% -1,220.84% -188.26% -3,534.20% -435.58%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -270.51 -13.97 -44.95 -34.91 -21.42 -46.85 -62.94 -45.30 -2.58 -759.55 -61,038.34
NOPAT to Interest Expense		 -170.34 -10.20 -29.97 -29.44 -10.45 -39.72 -46.69 -27.69 -3.16 -521.26 -42,726.64
EBIT Less CapEx to Interest Expense		 -270.51 -13.97 -44.95 -34.91 -21.42 -46.85 -62.94 -45.30 -2.58 -759.55 -61,038.34
NOPAT Less CapEx to Interest Expense		 -170.34 -10.20 -29.97 -29.44 -10.45 -39.72 -46.69 -27.69 -3.16 -521.26 -42,726.64
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Coeptis Therapeutics’ latest quarter shows a company still struggling to generate consistent operating profits, but with a relatively strong cash position and a balance sheet that improved materially versus prior periods. Revenue remains small and uneven, while operating losses continue to outweigh gross profit. The bigger picture is that the company has relied heavily on financing and share issuance to support operations.

  • Cash and equivalents rose to $5.2 million at the end of Q1 2026, up from $4.9 million in Q3 2025 and well above Q1 2025 levels.
  • Total current assets increased to $5.9 million, giving the company a more liquid near-term position.
  • Net change in cash was only a modest $(463,114) in Q1 2026, a significant improvement from the much larger operating cash burn seen in earlier periods.
  • The company generated some investment and financing cash inflows in Q1 2026, including $591,519 from sale/maturity of investments and $704,254 in other financing activities.
  • Total liabilities fell sharply to $2.2 million in Q1 2026 from $3.3 million in Q3 2025, suggesting a cleaner balance sheet.
  • Gross margin remained positive in Q1 2026, with $68,615 in gross profit on $113,771 of revenue.
  • Deferred revenue was $485,684 in Q1 2026, which could indicate some future revenue recognition if the business can execute.
  • Long-term debt stayed low at $150,000, while short-term debt was only $100,000 in Q1 2026.
  • Q1 2026 revenue was only $113,771, down sharply from $862,049 in Q4 2025, showing very limited top-line scale.
  • The company reported a Q1 2026 net loss of $(4.0 million) and an operating loss of $(3.9 million), highlighting that expenses still far exceed gross profit.
  • Operating cash flow was negative $(1.8 million) in Q1 2026, so the business is still burning cash from core operations.
  • Q1 2026 earnings per share were $(0.65), and prior quarters also showed persistent losses, indicating no clear profitability trend yet.
  • The company has repeatedly relied on equity issuance for cash, which can be dilutive to existing shareholders; this was especially evident in 2024 and 2025.
  • Shares outstanding have been volatile and generally much higher than in earlier periods, reflecting ongoing dilution and capital raises.

Overall: Coeptis Therapeutics appears better capitalized than it was a year ago, but the core business remains unprofitable and cash-generative performance is still negative. Investors should watch whether revenue can scale meaningfully and whether operating losses can narrow without additional dilution.

08/18/26 06:32 PM ETAI Generated. May Contain Errors.

Coeptis Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Coeptis Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Coeptis Therapeutics' net income appears to be on an upward trend, with a most recent value of -$12.28 million in 2025, rising from -$2.23 thousand in 2019. The previous period was -$10.88 million in 2024. Check out Coeptis Therapeutics' forecast to explore projected trends and price targets.

Coeptis Therapeutics' total operating income in 2025 was -$13.04 million, based on the following breakdown:
  • Total Gross Profit: $1.18 million
  • Total Operating Expenses: $14.23 million

Over the last 6 years, Coeptis Therapeutics' total revenue changed from $0.00 in 2019 to $1.36 million in 2025, a change of 136,304,500.0%.

Coeptis Therapeutics' total liabilities were at $120.00 at the end of 2025, a 100.0% decrease from 2024, and a 99.9% decrease since 2019.

In the past 6 years, Coeptis Therapeutics' cash and equivalents has ranged from $505.00 in 2019 to $3.79 million in 2022, and is currently $1.40 thousand as of their latest financial filing in 2025.

Over the last 6 years, Coeptis Therapeutics' book value per share changed from 0.01 in 2019 to 2.54 in 2025, a change of 27,807.7%.


Related Companies

Financial statements for NASDAQ:ZSQR last updated on 8/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your Free Report (Inside)
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
A Dark Day Is Coming to America
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel